Spatial downregulation of CD74 signatures may drive invasive component development in part-solid lung adenocarcinoma
Quick Facts
- Publication title: Spatial downregulation of CD74 signatures may drive invasive component development in part-solid lung adenocarcinoma
- Journal: iScience
- Year: 2023
- DOI: 10.1016/j.isci.2023.107699
- PMID/PMCID: 37810252; PMC10550719
Research overview
Pulmonary nodules with part-solid imaging features manifest during the progression from preinvasive to invasive lung adenocarcinoma. Higher immune infiltration was observed among MC1 regions in ST profiles, and further analysis revealed that macrophages may be involved in this process through the CD74 axis.
Key findings
Pulmonary nodules with part-solid imaging features manifest during the progression from preinvasive to invasive lung adenocarcinoma.
To define the spatial composition and evolutionary trajectories of early-stage lung adenocarcinoma, we combined spatial transcriptomics (ST) and pathological annotations from 20 part-solid nodules (PSNs), four of which were matched with single-cell RNA sequencing.
Two malignant cell populations (MC1 and MC2) were identified, and a linear evolutionary relationship was observed.
Compared to MC2, the pre-existing malignant MC1 exhibited a lower metastatic signature, corresponding to the preinvasive component (lepidic) on pathology and the ground glass component on PSN imaging.
Echo Biotech Role
Echo Biotech contributed single-cell RNA sequencing, spatial transcriptomics, integrated multi-omics analysis.
Related platforms: Exoomics®
Related services and capabilities: Single-Cell RNA Sequencing, Spatial Transcriptomics, Integrated Multi-omics Analysis
References
Original publication: Spatial downregulation of CD74 signatures may drive invasive component development in part-solid lung adenocarcinoma iScience. 2023. DOI: 10.1016/j.isci.2023.107699. PMID/PMCID: 37810252; PMC10550719.